{"entity":{"id":"trial-or-standard-treatment-biliary","kind":"term","name":"A clinical trial or standard treatment for gallbladder cancer","aka":[],"tldr":"Joining a trial is a decision like any other: the NHS explains that most trials compare a new treatment with the standard one, that a placebo is used only where no proven treatment exists, and that you can leave at any time without it affecting your care.","summary":"The NHS clinical trials page says \"a clinical trial compares the effects of 1 treatment with another\", that \"in most trials, a computer will be used to randomly decide which group each patient will be allocated to\", that people receive a placebo only \"if no proven standard treatment exists\", and that \"you can also choose to leave at any point without giving a reason and without it affecting the care you receive\". In gallbladder cancer the standard first treatment for cancer that has spread is gemcitabine and cisplatin with an immunotherapy antibody, so a trial in that setting normally adds something to that standard or compares two active treatments; in KEYNOTE-966 the control arm had chemotherapy plus placebo, never placebo alone.\n\nCancer Research UK mentions trials as an option at every stage of gallbladder cancer, and AMMF keeps a list of biliary trials open in the UK. Questions the NHS page suggests before joining: what the trial is trying to find out, how long it lasts, how many extra visits and tests are involved, whether travel costs are paid, what the side effects might be and what happens if the treatment is stopped. This is orientation from public patient pages, not advice for your case: your own team's instructions and 24-hour number come first.","asOf":"2026-09-24","links":[{"label":"NHS: clinical trials","url":"https://www.nhs.uk/tests-and-treatments/clinical-trials/"},{"label":"AMMF: clinical trials","url":"https://ammf.org.uk/clinical-trials/"},{"label":"Cancer Research UK: gallbladder cancer treatment decisions","url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/treatment/treatment-decisions"},{"label":"ESMO: biliary tract cancer, a guide for patients","url":"https://www.esmo.org/for-patients/patient-guides/biliary-tract-cancer-a-guide-for-patients"}],"tags":[],"related":[],"cancers":["gallbladder"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["clinical-trial","informed-consent","placebo"],"trials":["keynote-966","topaz-1","herizon-btc-302"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Trials"},"route":"/terms/trial-or-standard-treatment-biliary/","neighbours":{"cancer":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"informed-consent","kind":"term","name":"Informed consent","route":"/terms/informed-consent/"},{"id":"placebo","kind":"term","name":"Placebo","route":"/terms/placebo/"}],"trial":[{"id":"herizon-btc-302","kind":"trial","name":"HERIZON-BTC-302","route":"/trials/herizon-btc-302/"},{"id":"keynote-966","kind":"trial","name":"KEYNOTE-966","route":"/trials/keynote-966/"},{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/"}]}}